BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

M Bishop; I Flinn; P Borchmann; U Jaeger; J Westin; N Hamad; D Purtill; Richard Greil; S Thomas; T Teshima; H Harigae; C Garcia; P Barba; A Deol; P Shaughnessy; J Gu; G Andreola; MM Prieto; L Pacaud; S Schuster

BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

M Bishop, I Flinn, P Borchmann, U Jaeger, J Westin, N Hamad, D Purtill, Richard Greil, S Thomas, T Teshima, H Harigae, C Garcia, P Barba, A Deol, P Shaughnessy, J Gu, G Andreola, MM Prieto, L Pacaud, S Schuster

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Journal	JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume	7
Publication status	Published - 2019

Cite this

Bishop, M., Flinn, I., Borchmann, P., Jaeger, U., Westin, J., Hamad, N., Purtill, D., Greil, R., Thomas, S., Teshima, T., Harigae, H., Garcia, C., Barba, P., Deol, A., Shaughnessy, P., Gu, J., Andreola, G., Prieto, MM., Pacaud, L., & Schuster, S. (2019). BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7.

@article{516d8314904446baa6e2638333f8b36c,

title = "BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma",

author = "M Bishop and I Flinn and P Borchmann and U Jaeger and J Westin and N Hamad and D Purtill and Richard Greil and S Thomas and T Teshima and H Harigae and C Garcia and P Barba and A Deol and P Shaughnessy and J Gu and G Andreola and MM Prieto and L Pacaud and S Schuster",

year = "2019",

language = "English",

volume = "7",

journal = "JOURNAL FOR IMMUNOTHERAPY OF CANCER",

issn = "2051-1426",

}

Bishop, M, Flinn, I, Borchmann, P, Jaeger, U, Westin, J, Hamad, N, Purtill, D, Greil, R, Thomas, S, Teshima, T, Harigae, H, Garcia, C, Barba, P, Deol, A, Shaughnessy, P, Gu, J, Andreola, G, Prieto, MM, Pacaud, L & Schuster, S 2019, 'BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma', JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7.

TY - JOUR

T1 - BELINDA : A phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

AU - Bishop, M

AU - Flinn, I

AU - Borchmann, P

AU - Jaeger, U

AU - Westin, J

AU - Hamad, N

AU - Purtill, D

AU - Greil, Richard

AU - Thomas, S

AU - Teshima, T

AU - Harigae, H

AU - Garcia, C

AU - Barba, P

AU - Deol, A

AU - Shaughnessy, P

AU - Gu, J

AU - Andreola, G

AU - Prieto, MM

AU - Pacaud, L

AU - Schuster, S

PY - 2019

Y1 - 2019

M3 - Abstract (Journal)

SN - 2051-1426

VL - 7

JO - JOURNAL FOR IMMUNOTHERAPY OF CANCER

JF - JOURNAL FOR IMMUNOTHERAPY OF CANCER

ER -